Directorate Change

RNS Number : 8880F

Nuformix PLC

21 July 2021

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Nuformix plc

("Nuformix" or the "Company")

Directorate change

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that Dr Anne Brindley has decided to step down as CEO. Anne will continue in her current position for the next six months and has committed to assist the Company with an orderly transition for that period.

Alastair Riddell, Non-Executive Chairman of Nuformix, said: "Anne has been made an exceptional offer by another company which she wants to pursue. She is committed to ensuring the progress of the three assets in the Nuformix portfolio over the next six months and will continue to lead this process. In particular, managing the further preclinical work on NXP002 to deliver a more robust data package, the further research on NXP004 and concluding the licensing discussions on NXP001.

"We will be very sorry to see Anne go but we wish her all the very best in her future pursuits. We look forward to providing further updates to shareholders on the development of the portfolio of assets in the coming months."

Enquiries:

Nuformix plc			via Walbrook
Dr Alastair Riddell, Non-Executive Chairman
Dr Anne Brindley, CEO
Allenby Capital Limited			[phone]
Nick Athanas / George Payne (Corporate Finance)
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)
Walbrook PR	[e-mail] or [phone]
Anna Dunphy / Paul McManus / Kiki Zaccagnini		Tel: [phone]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com .

 

END

 

 

BOARMMFTMTMTBFB